Efavirenz - Still First-line King?

Expert Opinion on Drug Metabolism and Toxicology

Volumn 4, Issue 7, 2008, Pages 965-972

  Best, Brookie M ^a,b   Goicoechea, Miguel ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Antiviral Research Center   (United States)

Author keywords

Efavirenz; Novel antiretroviral agents; Treatment native

Indexed keywords

ANTIRETROVIRUS AGENT; ATAZANAVIR; CHOLESTEROL; DARUNAVIR; DARUNAVIR PLUS RITONAVIR; DELAVIRDINE; EFAVIRENZ; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ETRAVIRINE; INDINAVIR; LAMIVUDINE; LAMIVUDINE PLUS TENOFOVIR DISOPROXIL; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MARAVIROC; NELFINAVIR; NEVIRAPINE; PLACEBO; PROTEINASE INHIBITOR; RALTEGRAVIR; RILPIVIRINE; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR; TENOFOVIR DISOPROXIL; UNINDEXED DRUG;

ABNORMAL DREAMING; ABNORMAL LABORATORY RESULT; AGGRESSION; ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; BEDTIME DOSAGE; CD4 LYMPHOCYTE COUNT; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; CROSS RESISTANCE; DEPRESSION; DIARRHEA; DIZZINESS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG MONITORING; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FOOD; FOOD DRUG INTERACTION; GASTROINTESTINAL SYMPTOM; HALLUCINATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLIPIDEMIA; INSOMNIA; JAUNDICE; LIPOATROPHY; LIVER DISEASE; MACULOPAPULAR RASH; MAXIMUM PLASMA CONCENTRATION; MENTAL CONCENTRATION; MENTAL DISEASE; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NAUSEA; NEURAL TUBE DEFECT; NEUROLOGIC DISEASE; NONHUMAN; PARANOIA; REVIEW; SIDE EFFECT; SKIN MANIFESTATION; SOMNOLENCE; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; SUICIDAL IDEATION; TERATOGENICITY; UNSPECIFIED SIDE EFFECT; VIRUS LOAD; VOMITING;

ANIMALS; ANTI-HIV AGENTS; BENZOXAZINES; DRUG INTERACTIONS; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HUMANS; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 49649108542     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425255.4.7.965     Document Type: Review

References (48)

1. Panel on Antiretroviral Guidelines for Adolescents and Adults. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of health and human services. January 29, 2008;1-128. Available from: http://www.aidsinfo.nih.gov/ContentFiles/ AdultandAdolescentGL.pdf. Accessed May 14, 2008
2. Bristol-Myers Squib Company. Sustiva® prescribing information. Princeton, NJ. March 2008 [cited 2008 May 14]; Available from: www.sustiva.com
3. Young SD, Britcher SF, Tran LO, et al. L-743, 726 (DMP-266): a novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother 1995;39(12):2602-5
4. Witvrouw M, Pannecouque C, Switzer WM, et al. Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis. Antivir Ther 2004;9(1):57-65
5. Veldkamp AI, Harris M, Montaner JS, et al. The steady-state pharmacokinetics of efavirenz and nevirapine when used in combination in human immunodeficiency virus type 1-infected persons. J Infect Dis 2001;184(1):37-42
6. Villani P, Regazzi MB, Castelli F, et al. Pharmacokinetics of efavirenz (EFV) alone and in combination therapy with nelfinavir (NFV) in HIV-1 infected patients. Br J Clin Pharmacol 1999;48(5):712-5
7. Pfister M, Labbe L, Hammer SM, et al. Population pharmacokinetics and pharmacodynamics of efavirenz, nelfinavir, and indinavir: Adult AIDS Clinical Trial Group Study 398. Antimicrob Agents Chemother 2003;47(1):130-7
8. Haas DW, Ribaudo HJ, Kim RB, et al. Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. AIDS 2004;18(18):2391-400
9. Kappelhoff BS, Crommentuyn KM, de Maat MM, et al. Practical guidelines to interpret plasma concentrations of antiretroviral drugs. Clin Pharmacokinet 2004;43(13):845-53
10. Leth FV, Kappelhoff BS, Johnson D, et al. Pharmacokinetic parameters of nevirapine and efavirenz in relation to antiretroviral efficacy. AIDS Res Hum Retroviruses 2006;22(3):232-9
11. Marzolini C, Telenti A, Decosterd LA, et al. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS 2001;15(1):71-5
12. Nunez M, Gonzalez de Requena D, Gallego L, et al. Higher efavirenz plasma levels correlate with development of insomnia. J Acquir Immune Defic Syndr 2001;28(4):399-400
13. Bacheler LT, Anton ED, Kudish P, et al. Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapy. Antimicrob Agents Chemother 2000;44(9):2475-84
14. Joly V, Descamps D, Peytavin G, et al. Evolution of human immunodeficiency virus type 1 (HIV-1) resistance mutations in nonnucleoside reverse transcriptase inhibitors (NNRTIs) in HIV-1-infected patients switched to antiretroviral therapy without NNRTIs. Antimicrob Agents Chemother 2004;48(1):172-5
15. Brenner B, Turner D, Oliveira M, et al. A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors. AIDS 2003;17(1):F1-5
16. Loemba H, Brenner B, Parniak MA, et al. Polymorphisms of cytotoxic T-lymphocyte (CTL) and T-helper epitopes within reverse transcriptase (RT) of HIV-1 subtype C from Ethiopia and Botswana following selection of antiretroviral drug resistance. Antiviral Res 2002;56(2):129-42
17. Loemba H, Brenner B, Parniak MA, et al. Genetic divergence of human immunodeficiency virus type 1 Ethiopian clade C reverse transcriptase (RT) and rapid development of resistance against nonnucleoside inhibitors of RT. Antimicrob Agents Chemother 2002;46(7):2087-94
18. Tozzi V, Zaccarelli M, Narciso P, et al. Mutations in HIV-1 reverse transcriptase potentially associated with hypersusceptibility to nonnucleoside reverse-transcriptase inhibitors: effect on response to efavirenz-based therapy in an urban observational cohort. J Infect Dis 2004;189(9):1688-95
19. Shulman NS, Bosch RJ, Mellors JW, et al. Genetic correlates of efavirenz hypersusceptibility. AIDS 2004;18(13):1781-5
20. Clark SA, Shulman NS, Bosch RJ, Mellors JW. Reverse transcriptase mutations 118I, 208Y, and 215Y cause HIV-1 hypersusceptibility to non-nucleoside reverse transcriptase inhibitors. AIDS 2006;20(7):981-4
21. von Wyl V, Yerly S, Boni J, et al. Emergence of HIV-1 drug resistance in previously untreated patients initiating combination antiretroviral treatment: a comparison of different regimen types. Arch Intern Med 2007;167(16):1782-90
22. Lazzari S, de Felici A, Sobel H, Bertagnolio S. HIV drug resistance surveillance: summary of an April 2003 WHO consultation. AIDS 2004;18(Suppl 3):S49-53
23. Pillay D. Current patterns in the epidemiology of primary HIV drug resistance in North America and Europe. Antivir Ther 2004;9(5):695-702
24. Bartlett JA, Johnson J, Herrera G, et al. Long-term results of initial therapy with abacavir and Lamivudine combined with Efavirenz, Amprenavir/ Ritonavir, or Stavudine. J Acquir Immune Defic Syndr 2006;43(3):284-92
25. Squires K, Lazzarin A, Gatell JM, et al. Comparison of once-daily atazanavir with efavirenz each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV. J Acquir Immune Defic Syndr 2004;36(5):1011-9
26. van Leth F, Phanuphak P, Ruxrungtham K, et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet 2004;363(9417):1253-63
27. Clifford DB, Evans S, Yang Y, et al. Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals. Ann Intern Med 2005;143(10):714-21
28. Fumaz CR, Munoz-Moreno JA, Molto J, et al. Long-term neuropsychiatric disorders on efavirenz-based approaches: quality of life, psychologic issues, and adherence. J Acquir Immune Defic Syndr 2005;38(5):560-5
29. Lochet P, Peyriere H, Lotthe A, et al. Long-term assessment of neuropsychiatric adverse reactions associated with efavirenz. HIV Med 2003;4(1):62-6
30. Fundaro C, Genovese O, Rendeli C, et al. Myelomeningocele in a child with intrauterine exposure to efavirenz. AIDS 2002;16(2):299-300
31. Chersich MF, Urban MF, Venter FW, et al. Efavirenz use during pregnancy and for women of child-bearing potential. AIDS Res Ther 2006;3:11
32. Gulick RM, Ribaudo HJ, Shikuma CM, et al. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N Engl J Med 2004;350(18):1850-61
33. Goicoechea M, Best B. Efavirenz/emtricitabine/tenofovir disoproxil fumarate fixed-dose combination: first-line therapy for all? Expert Opin Pharmacother 2007;8(3):371-82
34. Maggiolo F. Efavirenz. Expert Opin Pharmacother 2007;8(8):1137-45
35. Vrouenraets SM, Wit FW, van Tongeren J, Lange JM. Efavirenz: a review. Expert Opin Pharmacother 2007;8(6):851-71
36. Albrecht MA, Bosch RJ, Hammer SM, et al. Nelfinavir, efavirenz, or both after the failure of nucleoside treatment of HIV infection. N Engl J Med 2001;345(6):398-407
37. Staszewski S, Morales-Ramirez J, Tashima KT, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. N Engl J Med 1999;341(25):1865-73
38. Manfredi R, Calza L, Chiodo F. First-line efavirenz versus lopinavir-ritonavir-based highly active antiretroviral therapy for naive patients. AIDS 2004;18(17):2331-3
39. Waters L, Stebbing J, Jones R, et al. A comparison of the CD4 response to antiretroviral regimens in patients commencing therapy with low CD4 counts. J Antimicrob Chemother 2004;54(2):503-7
40. Riddler SA, Haubrich R, DiRienzo G, et al. A prospective, randomized, Phase III trial of NRTI-, PI-, and NNRTI-sparing regimens for initial treatment of HIV-1 infection - ACTG 5142. XVI International AIDS Conference; 2006; Toronto, Canada
41. Haubrich R RS, DiRienzo G, Komartow L, et al., and the ACTG 5142 Team. Metabolic outcomes of AVTG 5142: a prospective, randomized, phase III trial of NRTI-, PI-, and NNRTI-sparing regimens for initial treatment of HIV-1 infection. 14th conference on retroviruses and opportunistic infections; 2007 February 25-28: Los Angeles, USA
42. Clumeck N vLJ, Chiliade P, et al. ARTEMIS: efficacy and safety of lopinavir (BID vs QD) and darunavir (QD) in antiretroviral-naive patients. European AIDS conference; 2007 October 24-27; Madrid, Spain
43. Markowitz M, Nguyen BY, Gotuzzo E, et al. Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study. J Acquir Immune Defic Syndr 2007;46(2):125-33
44. Saag MS IP, Heera J, et al. A multicenter, randomized, double-blind, comparative trial of a novel CCR5 antagonist, maraviroc versus efavirenz, both in combination with Combivir (zidovudine/lamivudine), for the treatment of antiretroviral naive subjects infected with R5 HIV-1: week 48 results of the MERIT study. 4th IAS conference on HIV pathogenesis, treatment, and prevention; 2007 July 22 - 25; Sydney, Australia
45. Lazzarin A, Campbell T, Clotet B, et al. Efficacy and safety of TMC 125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007;370(9581):39-48
46. Madruga JV, Cahn P, Grinsztejn B, et al. Efficacy and safety of TMC 125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007;370(9581):29-38
47. Pozniak A, Morales-Ramirez JO, Mohapi L, et al. 48-week primary analysis of trial TMC278-C204: TMC278 demonstrates potent and sustained efficacy in ART-naive patients. 14th Conference on Retrovirusses and Opportunistic Infections; 2007; Los Angeles, CA
48. Woodfall B, Vingerhoets J, Peeters M, et al. Impact of NNRTI and NRTI resistance on the response to the regimen of TMC125 plus two NRTIs in study TMC125-C227 [abstract no. 483]. 8th International congress on drug therapy in HIV infection; 2006 November 12 - 16; Glasgow, Scotland